Clinical Trial Update: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating rhIL-7-hyFc to increase lymphocyte counts in newly diagnosed glioma patients after radiation and temozolomide; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• rhIL-7-hyFc (recombinant human interleukin-7 fused to an Fc domain)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Glioma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-25